TELA Bio Inc. (TELA)
2.73
-0.01 (-0.36%)
At close: Jan 15, 2025, 12:39 PM
undefined% (undefined)
| Bid | 2.71 |
| Market Cap | 107.53M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.69 |
| PE Ratio (ttm) | -1.62 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.75 |
| Volume | 60,001 |
| Avg. Volume (20D) | 245,450 |
| Open | 2.67 |
| Previous Close | 2.74 |
| Day's Range | 2.67 - 2.77 |
| 52-Week Range | 2.30 - 7.84 |
| Beta | undefined |
About TELA
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and r...
Industry Medical - Devices
Sector Healthcare
IPO Date Nov 8, 2019
Employees 227
Stock Exchange NASDAQ
Ticker Symbol TELA
Website https://www.telabio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for TELA stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 266.30% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
TELA Bio Inc. is scheduled to release its earnings on Mar 20, 2025,
during market hours.
Analysts project revenue of $22.95M, reflecting a 35.02% YoY growth and earnings per share of -0.28, making a -47.17% decrease YoY.
Analysts project revenue of $22.95M, reflecting a 35.02% YoY growth and earnings per share of -0.28, making a -47.17% decrease YoY.
2 months ago ·
Source
-0.8%
TELA Bio shares are trading lower after the compan...
Unlock content with
Pro Subscription
5 months ago ·
Source
-22.94%
TELA Bio shares are trading lower after the company reported worse-than-expected Q2 financial results.
